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Abstract
In vitro data have shown that the hepatitis C virus (HCV) core protein binds to protein members
of the tumour necrosis factor receptor (TNFR) superfamily. Since this interaction could be
relevant to HCV persistence and oncogenesis, this study assessed whether HCV may interfere
with the apoptotic cascade in vivo. Apoptosis (by TUNEL) and Fas and TNFR1 expression (by
immunohistochemistry) were scored in the liver of 60 chronic hepatitis C patients. Results were
compared with the liver disease grading and staging scores and the HCV replication level in serum
and liver. Apoptotic hepatocytes were stained in 29 cases. Fas was expressed in 35 cases and
TNFR1 in 21, 15 patients (25%) being negative for both receptors. Overall, the numbers of
TUNEL-, Fas- and TNFR-positive hepatocytes did not correlate with the extent of intrahepatic
CD8+ T-lymphocyte infiltration, the grading and staging of liver disease, or the serum or liver
HCV RNA levels. Furthermore, when patients expressing either Fas or TNFR1 were stratified
according to serum HCV RNA levels, cases with detectable hepatocyte apoptosis had higher HCV
viraemias. In conclusion, an HCV-mediated, in vivo blockade of hepatocyte apoptosis via the Fas-
or TNFR1-dependent pathways seems unlikely. Copyright # 2002 John Wiley & Sons, Ltd.
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Introduction
The molecular cloning of the hepatitis C virus (HCV)
in 1989 marked the end of many years of searching for
an elusive agent responsible for non-A, non-B hepatitis
(NANB) [1]. A major clinical burden of HCV infection
is represented by its marked tendency to persist after
the acute phase [2]; also, a spontaneous recovery from
chronic HCV infection is rare [3]. This situation reflects
the inability of the host immune system to clear HCV
at all stages of infection. Recent data have shown that
an effective, specific cytotoxic T-lymphocyte (CTL)
response is critical to the elimination of HCV [4]. Since
such a response is invariably present in HCV-infected
individuals [5], why is it mostly ineffective?
The modulation of apoptosis signal transduction is
one of the several mechanisms proposed to account for
the persistence of HCV infection [5]. CTL-mediated
killing of hepatocytes occurs by triggering the apopto-
tic cascade via interaction of proteins on the lympho-
cyte membrane with specific receptors at the surface of
the target cell [6]. Three major systems are known to be
involved in this mechanism: the tumour necrosis
factor-a (TNF-a) and its receptors (TNFR1 and
TNFR2), the Fas-ligand and the Fas receptor, and
the perforin–granzyme system [7]. Several HCV pro-
teins have been reported, in a variety of transient or
stable in vitro expression systems, to modulate apop-
tosis of the transfected cells upon different stimuli
[8–18]. Moreover, some experimental data show that
the HCV nucleocapsid protein may interact non-
covalently with a cytoplasmic domain (the ‘death
domain’) of the lymphotoxin beta receptor and the
TNFR1 [10,12,19]. However, the data obtained in vitro
are contradictory, since in some cases the transfected
cells are protected against the apoptotic stimulus
[8,13,14,16], whereas in others they do not seem pro-
tected at all [15], and may even be sensitized [9–12].
The disparate effects of HCV proteins observed in vitro
are unexplained. They may depend on the physiologi-
cal status of the cell line, on genetic elements specific
to single HCV isolates, or on clonal variation within
the same tumour cell line, as well discussed in recent
reviews [20,21]. Sensitization to apoptosis may be dis-
advantageous for HCV, since it would lead to an
increased death rate of infected cells. In contrast, inhibi-
tion of the apoptosis cascade may be relevant for the
persistence of HCV infection, as shown for other
viruses [22], and may also be important in modulating
the oncogenic properties of HCV [20]. Neither pheno-
menon has so far been documented in vivo.
To evaluate whether this interaction may occur in
the liver of chronic hepatitis C patients, we studied the
level of liver cell apoptosis, as evaluated by terminal
deoxynucleotidyl transferase-mediated dUTP-biotin
nick end labelling (TUNEL) assay, and the expression
of some apoptosis mediators (Fas receptor and
TNFR1). We then correlated the results with the
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activity of liver disease, the extent of CD8+ infiltra-




We studied 60 chronic hepatitis C patients. All had
abnormal serum alanine aminotransferase activities;
persistent infection with HCV, as documented by
detection of HCV RNA in serum by a qualitative
RT-PCR assay (Amplicor2, Roche, Switzerland; sen-
sitivity limit 1000 copies/ml) for at least 6 months; and
histologically-proven chronic hepatitis.
A first group of controls included 24 chronic
hepatitis B patients. The two chronic hepatitis patient
groups were comparable in terms of liver disease grad-
ing and staging scores (Table 1). A further control
group included 24 histologically normal livers taken at
autopsy from patients who had died of extrahepatic
diseases.
This study conforms to the ethical guidelines of the
1975 Declaration of Helsinki.
Serum assays
Serum assays included detection of HCV RNA by the
above-mentioned qualitative RT-PCR and by a quan-
titative signal amplification-based, branched DNA
assay (Quantiplex2 version 2, Chiron Corp., Emery-
ville, CA, USA). HCV RNA genotyping was per-
formed by restriction fragment length polymorphism
(RFLP) [23].
Liver histology
Liver tissue was obtained from all patients by percu-
taneous biopsy performed for diagnostic purposes and
from the normal livers at autopsy. All tissue specimens
were fixed in 10% neutral buffered formalin and
paraffin-embedded. Five-micrometre sections were
stained with haematoxylin and eosin (H&E), reticulin,
Masson’s trichrome, and Perl’s stain. Histological dia-
gnosis was based on internationally accepted criteria,
which include a semi-quantitative assessment of liver
disease grading and staging [24].
Terminal deoxynucleotidyltransferase-mediated
dUTP-biotin nick end labelling (TUNEL)
TUNEL (Roche Diagnostic AG, Rotkreuz, Switzer-
land) was performed for the histological detection of
apoptosis of liver cells (hepatocytes and mononuclear
cells). Liver tissue sections were deparaffinized, re-
hydrated, and digested with 3 mg/ml proteinase K for
15 min at room temperature. After washing, sections
were incubated in 25 mM cobalt chloride, 0.01 mM
biotin-16-dUTP, and 25 U/ml terminal deoxynucleoti-
dyltransferase. After blocking endogenous peroxidase
by immersion in distilled water containing 25% H2O2
for 3 min, sections were washed, incubated with horse-
radish peroxidase-conjugated streptavidin, developed
in diaminobenzidine–H2O2, and counterstained with
haematoxylin. Positive hepatocytes were identified by
their location in hepatic cords and inflammatory cells
were identified by their position along sinusoids. The
positive nuclei were counted on high-power fields
(HPFs) (400r) and the numbers of apoptotic hepato-
cytes and inflammatory cells were scored separately.
Each HPF contained on average 250 hepatocytes. The
apoptotic index was defined as the number of TUNEL-
labelled cells per average HPF. It was calculated by
dividing the total number of positive cells by the total
number of HPFs scored on each specimen.
Immunohistochemistry
Immunohistochemical staining was performed using
primary antibodies to human Fas receptor (Dako
Diagnostic AG, Zug, Switzerland), TNFR1 (Santa Cruz,
Glaser AG, Basel, Switzerland), and CD8 (Dako).
Briefly, 3–5 mm sections were mounted on silane-coated
glass slides, deparaffinized, rehydrated, and pretreated
with H2O2/methanol to block endogenous peroxidase
activity. After incubation for 1 h at room temperature
with the diluted primary antibodies, reactions were
revealed with the avidin–biotin–peroxidase complex
method (Vectastain2, Vector, Switzerland). Peroxidase
activity was revealed with 30% 3,3k-diaminobenzidine
as chromogen in PBS containing 0.015% H2O2. Sec-
tions were counterstained with Mayer’s haematoxylin.
The degree of Fas receptor expression was semi-
quantitatively scored as follows: 0, none; 1, less than
1/3 of positive hepatocytes; 2, involvement of 1/3 to 2/3
of hepatocytes; and 3, more than 2/3 of positive hepa-
tocytes [25]. TNFR1 expression was evaluated qualita-
tively (detectable or undetectable) [26]. CD8+ lym-
phocytes were scored as follows: for portal infiltrates,
as a percentage of CD8+ cells vs. total inflammatory
cells, scored by H&E staining, with 0, none; 1, less
than 30% of portal inflammatory cells; 2, involvement
Table 1. Baseline characteristics and liver cell apoptosis









Lobular 1.78t0.92 1.7t1.06 NS
Periportal 1.78t0.98 1.74t1.32 NS
Portal 2.32t0.77 2.12t1.01 NS
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of 30–60% of portal inflammatory cells; and 3, greater
than 60% of portal inflammatory cells; for lobular
infiltrates as 0, none; 1, less than 1/3 of positive
lobules; 2, 1/3 to 2/3 positive lobules; and 3, more than
2/3 of positive lobules. The average, absolute number
of CD8+ cells per portal tract or per lobule was also
reported.
Strand-specific detection of genomic- and
negative-strand HCV RNA in the liver
A specimen adjacent to the one being processed for
routine histological studies was obtained in all 60 liver
biopsies, snap-frozen in liquid nitrogen, and stored at
x80uC. Total liver RNA was extracted by the acid
guanidinium thiocyanate–phenol–chloroform proce-
dure [27]. A strand-specific RT-PCR assay was used
to assess the presence and relative titres of either HCV
RNA strand [28,29]. Semi-quantitation was achieved
by performing a nested RT-PCR to the end point on
two- to four-fold dilutions [in 10 mg/ml Escherichia coli
tRNA (Sigma)] of an initial amount of 100 ng of total
liver RNA. Titres were expressed as the last dilution
giving a visible band of the appropriate size on a 1.6%
agarose gel stained by ethidium bromide. Intrahepatic
genomic- and minus-strand HCV RNA titres were nor-
malized to an arbitrary b-actin mRNA titre of 1024,
as measured on the same specimen [30]. The strand
specificity, sensitivity, and reproducibility of the
RT-PCR detection of liver HCV RNA have been
reported before [28]. In particular, this assay was
shown to detect as few as 15 copies of each HCV RNA
strand per assay, independently of genotype [29].
Statistical analysis
Apoptotic indices are reported throughout the Results
section as averagetSD. However, before statistical
analysis, both apoptotic indices and serum HCV RNA
levels were log10-transformed. Differences were evalu-
ated by the Mann–Whitney U-test. The coefficients of
correlation among non-parametric variables were
evaluated by Spearman’s rank correlation test. Tables
of contingency were evaluated by the x2-method or
Fisher’s exact test, when appropriate.
Results
Frequency and distribution of intrahepatic
apoptosis
TUNEL-labelled nuclei were single and widely scat-
tered within the liver (Figure 1a). Positive hepatocytes
were seen both in the periportal and in the intralobular
areas. Infiltrating mononuclear cells were stained in
both portal tracts and lobules. In chronic hepatitis
C patients, the hepatocellular apoptotic index ranged
from 0 to 0.1 cells per HPF (0.017t0.024). In 31/60
Figure 1. Light microscopy of a tissue section from a patient with chronic hepatitis C. (a) Two apoptotic hepatocytes located at the
level of interface hepatitis show Tunel-positive nuclei. (b) Immunohistochemical staining reveals strong and diffuse membranous
expression of Fas receptor on hepatocytes. (c) TNFR1 is expressed in perinuclear cytoplasm of some hepatocytes. (d) Several
CD8+ lymphocytes are concentrated at the level of interface hepatitis and are sparsely distributed in the lobules. r360
Apoptosis in chronic hepatitis C 619
Copyright # 2002 John Wiley & Sons, Ltd. J Pathol 2002; 197: 617–623.
cases (52%), hepatocellular apoptosis was undetect-
able. The infiltrating mononuclear cell apoptotic index
ranged from 0 to 0.194 cells per HPF (0.016t0.035).
In 39/60 cases (65%), no mononuclear cells were stained
for apoptosis.
In chronic hepatitis B patients, the hepatocellular
apoptotic index ranged from 0 to 0.118 cells per HPF
(0.026t0.035). In 12/24 cases (50%), hepatocellular
apoptosis was undetectable. The infiltrating mono-
nuclear cell apoptotic index ranged from 0 to 0.3 cells
per HPF (0.06t0.076). Infiltrating cells could not be
stained in eight cases (33%).
There was no statistically significant difference in the
apoptotic index of hepatocytes between chronic hepa-
titis C and chronic hepatitis B patients (p=0.218)
(Table 1). In contrast, not only were the infiltrating
mononuclear cells more frequently stained in chronic
hepatitis B than in chronic hepatitis C patients
(p=0.015), but the apoptotic index was significantly
higher in the former than in the latter (p<0.001).
The histologically normal livers had a hepatocyte
apoptotic index of 0.004t0.006 cells per HPF. This
value was significantly lower than that observed in
chronic hepatitis C (p=0.011) and chronic hepatitis B
(p=0.006) patients.
Frequency and distribution of apoptosis
mediators by immunohistochemistry
Among 60 liver specimens of patients with chronic
hepatitis C, Fas receptor staining was present on the
hepatocellular membrane in 35 cases (58.3%) (Figure
1b). The Fas receptor staining score was 0 in 25 cases
(41.7%), 1 in 18 (30%), 2 in 11 (18.3%), and 3 in 6
(10%). TNFR1 in hepatocytes was detected in 21 cases
(35%) (Figure 1c). In 15 patients, neither Fas nor
TNFR1 could be detected by immunohistochemistry.
Expression of CD8 in infiltrating mononuclear
cells
CD8+ cells were detected in all 32 cases where
material was available for study (Figure 1d). In all
cases, CD8+ cells were found in both the portal tracts
and the lobules. The distribution of CD8+ cells in
portal tracts was diffuse in 27 cases and predominantly
at the interface in five cases.
The scores of CD8 portal staining varied from 1 in
18 cases (56.2%), 2 in 11 cases (34.4%) to 3 in three
cases (9.4%). The scores of CD8 lobular staining varied
from 1 in 18 cases (56.2%), 2 in eight cases (25.6%) to 3
in six cases (19.2%). In no liver specimen were the
inflammatory infiltrates completely devoid of CD8+
cells. The absolute number of CD8+ cells was 30.4t
13.7 cells per portal tract, and did not correlate with
either the hepatocellular (r=0.15) or the infiltrating
mononuclear cell apoptotic index (r=0.13). Similarly,
the absolute number of CD8+ cells per lobule was
19.9t11.2 cells: again, this failed to correlate with
either the hepatocellular (r=x0.33) or the infiltrating
mononuclear cell apoptotic index (r=x0.16).
Correlation of apoptosis scores and expression
levels of apoptosis mediators with liver histology
We could not establish any correlation between the
apoptotic indices and the expression pattern/level of Fas
or TNFR1 (data not shown). The hepatocellular apop-
totic index did not correlate with the lobular (r=x0.17),
periportal (r=x0.15) or portal (r=0.18) inflammatory
scores, or with the fibrosis score (r=x0.09). Similarly,
the infiltrating mononuclear cell apoptotic index was not
correlated with the lobular (r=x0.22), periportal
(r=x0.05) or portal (r=0.04) inflammatory scores, nor
with the fibrosis score (r=0.18).
Expression of liver cell apoptosis/apoptosis mediator
scores and HCV genotype and replication level
Among the 57 patients in whom the HCV genotype
could be determined, 23 were infected with type 1,
eight with type 2, 19 with type 3, and seven with type 4.
In three patients, we could not assign the viral type,
based on the above RFLP method. The highest
hepatocellular apoptotic index was found in patients
infected with HCV type 1 (0.021t0.027 cells per
HPF), whereas patients with types 2, 3, and 4 had
0.005t0.013, 0.017t0.025, and 0.013t0.017 cells per
HPF, respectively. Moreover, none of these differences
was statistically significant. The highest infiltrating
mononuclear cell apoptotic index was again that of
patients with type 1, with a value of 0.025t0.047 cells
per HPF. In patients with types 2, 3, and 4, the infil-
trating mononuclear cell apoptotic index was 0.007t
0.013, 0.007t0.012, and 0.021t0.045 cells per HPF,
respectively. Again, none of these differences reached
statistical significance.
Overall, there was no correlation between the expres-
sion pattern/level of apoptosis mediators and apoptotic
indices, on the one hand, and the serum HCV RNA
levels or the intrahepatic genomic- and negative-strand
HCV RNA titres on the other hand (data not shown).
We then divided patients into several groups,
depending on the following parameters: (1) presence/
absence of detectable apoptosis in hepatocytes or
mononuclear cells; and (2) levels of HCV RNA in
serum higher/lower than an arbitrary threshold level of
1 000 000 genome-equivalents/ml.
Table 2 shows the distribution of all patients,
Table 2. Presence of TUNEL-positive liver cells according





pAPO+ APOx APO+ APOx
Serum HCV RNA level
>1 000 000
genome-Eq/ml
22 20 NS 16 26 NS
<1 000 000
genome-Eq/ml
7 11 9 9
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irrespective of the expression of the apoptosis receptors
in the liver. There was no association between the level
of HCV replication and the presence of TUNEL-
positive cells in the liver.
Table 3 shows a similar stratification, but limited to
patients in whom the Fas receptor could be stained
(irrespective of the staining score). Although the
nuclear TUNEL staining of infiltrating cells was not
associated with the level of HCV replication, the hepa-
tocyte apoptotic index was significantly higher among
the patients with higher serum HCV RNA levels
(p=0.01). Similarly, the hepatocytes (but not the infil-
trating cells) were more likely to be apoptotic among
patients expressing TNFR1 and having higher levels of
HCV viraemia (Table 4) (p=0.02).
Finally, and in contrast with the above, when neither
Fas nor TNFR1 was detected, higher levels of HCV
RNA in serum were significantly associated with the
lack of detectable hepatocyte apoptosis (Table 5)
(p=0.009). For liver infiltrating cells, the association
approached, but did not reach, statistical significance
(p=0.06).
Discussion
The high tendency of HCV to establish a chronic
infection is unexplained, although several mechanisms
have been postulated [5]. The possible interaction with
the apoptotic cascade is an attractive one, since it may
also account for the oncogenic potential of HCV
[17,20,21,31]. Several HCV proteins have been shown
to alter the effect of apoptotic stimuli on in vitro
transfected cell lines. The proteins studied include the
core protein [8–15], the non-structural (NS) protein 3
[18], and NS5A [17]. In some cases, a direct, non-
covalent interaction of the core protein with the death
domain of the lymphotoxin beta receptor [10,19] and
of TNFR1 [12] was reported. However, the effects of
viral proteins in these systems vary markedly, as they
may alternatively protect the transfected cells from
apoptosis, or sensitize them. To add further to the
confusion, the effects of the same proteins (mostly the
core protein) on the activation of specific transcription
factors involved in the apoptotic signalling pathways
(such as NFkB) are far from being unequivocal
[12,14,16,31,32]. The reasons for these discrepancies
are unclear and they may depend on several factors
[21]. Clearly, an inhibition of the apoptotic cascade
would be advantageous for HCV, since it may enhance
viral replication and contribute to viral persistence and
oncogenesis. Inhibition of apoptosis has been shown in
several viral infections [22]. Mechanisms vary from the
direct encoding of anti-apoptotic molecules by the viral
genome (such as homologues to cellular proteins invol-
ved in apoptosis regulation, e.g. caspase inhibitors,
serpins, and cytokine receptors), to the up-regulation
of cell anti-apoptotic genes (such as Bcl2 and A20) or
the down-regulation of pro-apoptotic factors (such as
Bax), to the induction of Fas-ligand [22]. These effects
converge towards the protection of infected cells by
cell-autonomous apoptosis and/or towards the evasion
of viral antigen-specific cytotoxic lymphocyte killing
[22].
In the present study, we noted that the overall
apoptotic index of hepatocytes was comparable to that
of a control population infected with HBV. We also
saw that all liver specimens had a CD8+ infiltrate and
that most of them expressed Fas or TNFR1, or both.
However, we still wanted to analyse whether HCV
could interact with some members of the death recep-
tor family (Fas and TNFR1). We assumed that the
effect that may be likely to prevail in vivo (if any) is the
inhibition of the apoptotic cascade; hence we analysed
the correlation between level of apoptosis and HCV
replication. We based this assumption on several clini-
cal observations: first, the high tendency to persistence
of acute HCV infection; and second, the fact that both
autoimmune phenomena and malignancies of both the
Table 3. Presence of TUNEL-positive liver cells according
to serum HCV RNA levels in 35 chronic hepatitis C




pAPO+ APOx APO+ APOx
Serum HCV RNA level
>1 000 000
genome-Eq/ml
17 8 0.01 11 14 NS
<1 000 000
genome-Eq/ml
2 8 2 8
Table 4. Presence of TUNEL-positive liver cells according
to serum HCV RNA levels in 21 chronic hepatitis C




pAPO+ APOx APO+ APOx
Serum HCV RNA level
>1 000 000
genome-Eq/ml
12 2 0.02 7 7 NS
<1 000 000
genome-Eq/ml
4 3 2 5
Table 5. Presence of TUNEL-positive liver cells according
to serum HCV RNA levels in 15 chronic hepatitis C





pAPO+ APOx APO+ APOx
Serum HCV RNA level
>1 000 000
genome-Eq/ml
0 11 0.009 0 11 0.06
<1 000 000
genome-Eq/ml
3 1 2 2
Apoptosis in chronic hepatitis C 621
Copyright # 2002 John Wiley & Sons, Ltd. J Pathol 2002; 197: 617–623.
liver and the haematopoietic lineage have been found
to be associated with HCV infection, especially pri-
mary liver cancer and a subset of B-cell non-Hodgkin
lymphoma [33]. Defects in the control of the immune
system homeostasis by apoptosis are in fact relevant
for the pathogenesis of both autoimmune and lympho-
proliferative disorders [34] and another study suggests
that even other extrahepatic malignancies may be more
frequent in HCV-infected patients than in the general
population [35].
At variance with our expectations, we found that
when only patients expressing Fas or TNFR were con-
sidered (the two death receptors most studied in vitro),
higher levels of HCV replication were found in patients
in whom hepatocyte apoptosis was more easily
detected. So, HCV replication not only does not seem
to protect from apoptosis, when Fas or TNFR1 is
expressed, but it may even sensitize infected cells to the
apoptotic stimulus, in agreement with some in vitro
data [9–12]. We must emphasize the fact that the
inverse relationship between viral replication and levels
of apoptosis was not evident when all the patients were
considered and this may be due to the fact that the
sensitizing effect seen in Fas- and/or TNFR-positive
patients was counterbalanced by a ‘protective’ effect in
patients lacking the expression of both death receptors.
In this small subgroup, in fact, higher levels of HCV
replication were found in patients in whom hepatocyte
apoptosis was below the threshold of the TUNEL
assay. We also have to assume that the simple intra-
hepatic expression of Fas or TNFR1 may not be suffi-
cient to trigger hepatocyte apoptosis, since this may
require a specific intracellular environment. For exam-
ple, TNF engagement with TNFR1 triggers apoptosis
only if protein synthesis is simultaneously inhibited,
such as by the virally induced activation of PKR
(reviewed in [ref. 21]). HCV has been shown to rescue
the PKR-mediated inhibition of translation and cells
expressing the viral NS5a protein alone become refrac-
tory to apoptosis [36]. So, if the inhibition of protein
synthesis is a prerequisite of apoptosis activation via
TNF-a, it probably results from mechanisms other
than activation of PKR. The analysis of these inter-
actions was beyond the scope of the present study and
probably only a single-cell analysis by combined
immunohistochemistry and/or in situ hybridization
imaging techniques may appropriately address this
issue in the future.
Finally, as far as the apoptotic indices of infiltrating
mononuclear cells are concerned, we could establish no
correlations with the HCV replicative levels or with
any other parameter. The only exception may be repre-
sented by patients not expressing either Fas or TNFR1, in
whom the association between higher viraemia levels
and undetectable apoptosis of mononuclear cells
approached statistical significance. This association is
worth studying in a larger population of patients, also
taking into consideration the HCV tropism for mono-
nuclear cells [37–39]. Furthermore, the apoptotic index
of mononuclear cells in the control group of patients
with chronic hepatitis B was significantly higher than
that found in chronic hepatitis C patients. This differ-
ence is unexplained and may have interesting implica-
tions as to the persistence and pathogenesis of HBV
infection.
Thus, we suggest that two populations of chronic
hepatitis C patients seem to exist, in whom the interaction
between HCV product(s) and the apoptotic pathway(s)
may differ. When Fas or TNFR is expressed, the degree
of apoptosis of infected cells (either spontaneous or
CTL-mediated) seems to increase in parallel with viral
replication. In other words, the Fas- and TNFR-
dependent apoptotic pathways may not be blocked
by HCV. Since all of these patients have a chronic
hepatitis, HCV probably exploits alternative pathways
to evade immune recognition, other than interfering
with apoptosis. A second group of chronically HCV-
infected patients may exist, however, in whom HCV
may block hepatocyte apoptosis via pathways other
than the Fas- or TNFR-dependent ones. Why the
immune system fails to activate proper expression of
Fas and TNFR in these patients is unknown. The anti-
apoptotic strategy of HCV in these cases can only be a
matter of speculation. Recently [40], the t(14;18) trans-
location and Bcl2 overexpression in lymphoid cells
were observed in chronic hepatitis C patients. Since HCV
infects B cells [36–38], a direct interaction between one
or more HCV product(s) and the anti-apoptotic BCL2
activity cannot be excluded, and may be worth inves-
tigating also in hepatocytes, which are the primary
target of HCV replication [41,42].
In conclusion, if HCV exerts anti-apoptotic activity
in vivo, this does not seem to be mediated by an
interaction with the Fas- or the TNFR-dependent
pathways. Our data, however, seem to suggest that an
anti-apoptotic effect may be acting in a small propor-
tion of chronic hepatitis C patients, via undetermined
mechanisms, which warrant further investigation.
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